Lara Sullivan | President and Founder
SpringWorks Therapeutics

Lara Sullivan, President and Founder, SpringWorks Therapeutics

Lara Sullivan brings to SpringWorks Therapeutics more than two decades of experience and senior leadership in biopharmaceuticals, healthcare and life sciences, most recently at Pfizer.  While at Pfizer she helmed strategy and portfolio operations for the company’s early stage pipeline and led the work, inside Pfizer and with outside patient groups and partners, to create SpringWorks Therapeutics.  Lara joined Pfizer from McKinsey & Company, where she was an associate partner in the pharmaceutical and medical products practice advising biopharmaceutical clients on a variety of strategic and operational issues, with a particular emphasis on R&D productivity.  Additionally, Lara was a principal at Paul Capital Partners leading due diligence for investments in the healthcare fund, and earlier in her career worked in healthcare equity research and municipal finance at CS First Boston.  Lara holds an M.D. from the University of Pennsylvania School of Medicine, an MBA from The Wharton School at the University of Pennsylvania, and a B.A. in comparative literature from Cornell University.

Appearances:



World Orphan Drug Congress USA 2018 - Conference Day One @ 11:25

Collaborative mission-driven approach to developing innovative potential new treatments for unserved and underserved patient communities

  • Addressing industry challenges of too much good science and insufficient resources to fully advance pipelines 
  • Aligning biopharma innovators with investigators, patient groups, and funders to advance promising investigational therapies 
  • Concept in Action: Big Pharma expertise and capabilities leveraged to enable company launch pipeline of four mid- and late -stage clinical assets, enabling strong Series A funding

back to speakers